Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery

Quoin Pharmaceuticals ( (QNRX) ) just unveiled an update.

On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of target loading concentrations for its two topical rapamycin delivery technologies. A 4% concentration was achieved in their topical formulation and a 5% concentration in a dermal patch system. The company plans to manufacture clinical trial batches this quarter and begin clinical testing in the first half of 2026, targeting conditions like Microcystic Lymphatic Malformations and Venous Malformations, for which there are currently no FDA-approved treatments.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company aims to address unmet medical needs with an innovative pipeline targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, and various malformations.

Average Trading Volume: 607,415

Technical Sentiment Signal: Sell

Current Market Cap: $4.79M

Learn more about QNRX stock on TipRanks’ Stock Analysis page.